On March 2, 2022, the Office of Inspector General (“OIG”) for the Department of Health and Human Services (“HHS”) posted an advisory opinion concluding that a digital program for the treatment of substance use disorders would raise minimal fraud and abuse risk. OIG advisory opinions address the application of certain
Continue Reading OIG Issues Advisory Opinion on Digital Program for the Treatment of Substance Use Disorders

Beth Braiterman
Beth Braiterman is an associate in the firm’s Washington, DC office, where she is a member of the Food, Drug, and Device and Health Care Practice Groups. She advises pharmaceutical, biotechnology, medical device, and food companies on a variety of regulatory and compliance issues.